AACR 19/07/10

Authors' Affiliations:1The Fred Hutchinson Cancer Research Center, Cancer Prevention Unit; 2Department of Epidemiology, University of Washington, Seattle, Washington and 3Department of Family and Preventive Medicine, University of California, San Diego, California
Background: Use of nonvitamin, nonmineral “specialty” supplements has increased substantially over recent decades. Several supplements may have anti-inflammatory or anticancer properties. Additionally, supplements taken for symptoms of menopause have been associated with reduced risk of breast cancer in two case-control studies. However, there have been no prospective studies of the association between the long-term use of these supplements and breast cancer risk.
Methods: Participants were female members of the VITamins And Lifestyle (VITAL) Cohort.

Archieves of Neurology  07/07/10

Objective  To investigate whether serum vitamin D level predicts the risk of Parkinson disease.
Design  Cohort study.
Setting  The study was based on the Mini-Finland Health Survey, which was conducted from 1978 to 1980, with Parkinson disease occurrence follow-up through the end of 2007. During the 29-year follow-up period, 50 incident Parkinson disease cases occurred. Serum 25-hydroxyvitamin D level was determined from frozen samples stored at baseline. Estimates of the relationship between serum vitamin D concentration and Parkinson disease incidence were calculated using the Cox model.
Participants  Three thousand one hundred seventy-three men and women, aged 50 to 79 years and free of Parkinson disease at baseline.

Worldhealth 12/07/2010
 
In that a number of previous studies have found that antioxidant supplementation has the potential to alleviate the atherosclerotic damage caused by excessive production of reactive oxygen species (ROS), Reuven Zimlichman, from Tel Aviv University (Israel), and colleagues evaluated the effects of prolonged antioxidant treatment on arterial elasticity, inflammatory and metabolic measures in patients with multiple cardiovascular risk factors. 

Worldhealth 30/06/2010

Arthur A. Stonea,1, Joseph E. Schwartza,b, Joan E. Brodericka, and Angus Deatonc
+ Author Affiliations

aDepartment of Psychiatry and Behavioral Science, Stony Brook University, Stony Brook, NY 11794-8790;
bCenter for Behavioral and Cardiovascular Health, Columbia University Medical Center, New York, NY 10032; and
cWoodrow Wilson School and the Department of Economics, Princeton University, Princeton, NJ 08544
Edited* by Daniel Kahneman, Princeton University, Princeton, NJ, and approved April 20, 2010 (received for review March 22, 2010)

The American Journal of Clinical Nutrition 30/06/10

Bamini Gopinath, Victoria M Flood, Elena Rochtchina, Catherine M McMahon and Paul Mitchell
1 From the Centre for Vision Research, Department of Ophthalmology, and Westmead Millennium Institute (BG, ER, and PM), and the Menzies Centre for Health Policy (BG), University of Sydney, Sydney, Australia; the Faculty of Health and Behavioural Science, University of Wollongong, Wollongong, Australia (VMF); and the Centre for Language Sciences, Linguistics Department, Macquarie University, Sydney, Australia (CMM).

2 The Blue Mountains Eye Study and Hearing Study were supported by the Australian National Health and Medical Research Council (grants 974159, 991407, 211069, and 262120).

3 Address correspondence to P Mitchell, Centre for Vision Research, University of Sydney, Westmead Hospital, Hawkesbury Rd, Westmead, NSW 2145, Australia.